治疗急性心力衰竭与乙醇胺的治疗
Kassidy Veasaw1, Uzair Mahmood2, Tzvi Fishkin1
1From the Department of Medicine.
Cardiology in review
|September 27, 2023
概括
循环利尿剂是急性心力衰竭的标准,但耐药性很常见. 本综述探讨了乙醇胺作为一种潜在的替代或补充疗法,用于改善心力衰竭患者的脱血.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉循环利尿剂是急性心力衰竭的主要治疗方法,以缓解堵塞.
- 适当的疏堵对于改善治疗结果,降低死亡率和防止再住院至关重要.
- 利尿剂耐药性是一个重大挑战,往往需要替代或补充疗法.
研究的目的:
- 审查新出现的关于使用乙胺在治疗急性心力衰竭方面的证据.
- 评估乙胺作为急性心力衰竭和利尿剂耐药性患者的潜在治疗选择.
主要方法:
- 最近研究和临床试验的文献综述.
- 对药理学数据和与急性心力衰竭中乙胺使用相关的临床结果的分析.
主要成果:
- 讨论乙醇胺在利尿症中的作用机制.
- 介绍目前关于乙醇胺在急性心力衰竭中的有效性和安全性的证据.
- 乙胺与传统的补充疗法 (如 thiazides) 的比较.
结论:
- 乙醇胺显示承诺作为一个有效的代理在急性心力衰竭的脱血.
- 需要进一步的研究来确定乙醇胺在心力衰竭管理中的最佳使用和长期益处.
相关概念视频
Heart Failure Drugs: Diuretics
412
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
412
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Acute Kidney Injury V: Interprofessional Care
12
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
12
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611


